Medicus Pharma Shows 55% BCC Clearance and Unveils Endometriosis Precision Trial
MDCX•Medicus Pharma will present Phase 2b data showing SkinJect 200 μg achieved 55% histological and 64% clinical BCC clearance, and will discuss pending Orphan Drug and Rare Pediatric Disease designations for Gorlin Syndrome. The company will also review Teverelix’s advanced prostate cancer modification submission, AUR relapse program and PRECISION-E2 endometriosis trial.
1. Bio International Presentation
Medicus Pharma will present on June 24 at Bio International 2026 in San Diego, highlighting clinical, regulatory and strategic developments across its SkinJect and Teverelix programs.
2. SkinJect Phase 2b SKNJCT-003 Results
The Phase 2b study in basal cell carcinoma showed a clear dose-response, with the 200 µg cohort achieving 55% histological clearance and 64% clinical clearance. Medicus has requested Orphan Drug and Rare Pediatric Disease designations for SkinJect in Gorlin Syndrome, both currently under FDA review.
3. Teverelix Development Pipeline
Medicus will detail Teverelix’s substantial modification submission to the EU CTIS for a Phase 2b prostate cancer dose-optimization study, progress in the acute urinary retention relapse program, and the newly initiated PRECISION-E2 Phase 2a endometriosis trial integrating UAE genomic profiling for precision patient selection.
